A study of intense neoadjuvant testosterone lowering therapy with goserelin and enzalutamide (Enza) in high-risk prostate cancer (PC) with multiparametric MRI (mpMRI).

Authors

null

Fatima Karzai

National Cancer Institute at the National Institutes of Health, Bethesda, MD

Fatima Karzai , Ravi Amrit Madan , David James VanderWeele , Guinevere Chun , Marijo Bilusic , Lisa M. Cordes , Nicole Carrabba , Scott Wilkinson , Huihui Ye , Stephanie Harmon , Adam G. Sowalsky , Baris Turkbey , Peter A. Pinto , Peter L. Choyke , James L. Gulley , William L. Dahut

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2019 Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session A: Prostate Cancer

Track

Prostate Cancer,Prostate Cancer

Sub Track

Prostate Cancer - Localized Disease

Clinical Trial Registration Number

NCT02430480

Citation

J Clin Oncol 37, 2019 (suppl 7S; abstr 63)

DOI

10.1200/JCO.2019.37.7_suppl.63

Abstract #

63

Poster Bd #

D9

Abstract Disclosures

Similar Posters

Poster

2018 ASCO Annual Meeting

Neoadjuvant androgen deprivation therapy and enzalutamide: Imaging and pathological responses.

Neoadjuvant androgen deprivation therapy and enzalutamide: Imaging and pathological responses.

First Author: David James VanderWeele

Poster

2019 Genitourinary Cancers Symposium

Molecular and imaging correlates of exceptional pathologic response to neoadjuvant ADT plus enzalutamide.

Molecular and imaging correlates of exceptional pathologic response to neoadjuvant ADT plus enzalutamide.

First Author: Adam G. Sowalsky